A Covid Competition Dilemma: Legal and Ethical Challenges Regarding the Covid-19 Vaccine Policies during and after the Crisis

doi: 10.53116/pgaflr.2021.1.5


The Covid-19 pandemic has impacted multiple facets of our lives and created a number of legal and ethical dilemmas. One of the greatest challenges at present is the production and distribution of the Covid-19 vaccine. Refusing to supply Covid vaccines widely could affect millions worldwide, and the pandemic may last for a long time. The competition authorities’ monitoring of the health sector in many countries has been subject to changes in the
current crisis. The question is whether we can force the Covid-19 vaccine manufacturers, legally and ethically, to sell their products and share their information with their competitors. Furthermore, what are the post-pandemic consequences of policies adopted during the pandemic? This paper employs a descriptive-analytical method to examine the importance of competition and intellectual property policies as they relate to Covid-19. It concludes that instead of focusing on individual rights in a crisis, public rights need to be emphasised. However, we should not underestimate the post-pandemic consequences of policies adopted during the Covid-19 pandemic.


COVID-19 Competition Law Vaccine Policy Ethics Intellectual Property

How to Cite

Hosseini, M. (2021). A Covid Competition Dilemma: Legal and Ethical Challenges Regarding the Covid-19 Vaccine Policies during and after the Crisis. Public Governance, Administration and Finances Law Review, 6(1), 51–63. https://doi.org/10.53116/pgaflr.2021.1.5


Authority for Consumers and Markets (2021). ACM has Confidence in Commitments Made by Roche to Help Solve Problems with Test Materials. Online: https://www.acm.nl/en/publications/acm-has-confidence-commitments-made-roche-help-solve-problems-test-materials

Bagley, M. A. (2017). The Morality of Compulsory Licensing as an Access to Medicines Tool. Minnesota Law Review 102, 2463–2494.

Balsam, K. F., Martell, Ch. R., Jones, K. P. &Safren, S. A. (2019). Affirmative Cognitive Behavior Therapy with Sexual and Gender Minority People. In G. Y. Iwamasa & P. A. Hays (Eds.), Culturally Responsive Cognitive Behavior Therapy: Practice and Supervision (2nd ed., pp. 287–314). American Psychological Association. Online: https://doi.org/10.1037/0000119-012

Bollyky, T. J., Gostin, L. O. & Hamburg, M. A. (2020). The Equitable Distribution of COVID-19 Therapeutics and Vaccines. Journal of the American Medical Association, 323(24), 2462–2463. Online: https://doi.org/10.1001/jama.2020.6641

Bonadio, E. & Fontanelli, F. (2021). Push for COVID-19 Vaccine Patent Waiver isn’t a Panacea: But it could Nudge Companies to Share. Online: https://theconversation.com/push-for-covid-19-vaccine-patent-waiver-isnt-a-panacea-but-it-could-nudge-companies-to-share-160802

Bourla, A. (2021). An Open Letter from Albert Bourla to Pfizer Employees. Online: https://www.pfizer.com/news/hot-topics/why_pfizer_opposes_the_trips_intellectual_property_waiver_for_covid_19_vaccines

Brown, L. S. (2018). Feminist Therapy (2nd ed.). American Psychological Association. Online: https://doi.org/10.1037/0000092-000

Catania, L. J. (2021). SARS-CoV-2 and the COVID-19 Pandemic. Foundations of Artificial Intelligence in Healthcare and Bioscience. Online: https://doi.org/10.1016/b978-0-12-824477-7.00004-3

Competition and Markets Authority (2020). An Open Letter to the Pharmaceutical and Food and Drink Industries. Online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/874240/COVID_19_Open_letter_to_pharmaceutical_and_food_and_drink_industries2.pdf

Competition and Markets Authority (2021). CMA Approach to Business Cooperation in Response to COVID-19. Online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/87 5468/Covid19_guidance_-.pdf

Costa-Cabral, F., Hancher, L., Monti, M. & Ruiz Feases, A. (2021). EU Competition Law and COVID-19. TILEC Discussion Paper No. DP2020-007. Online: https://ssrn.com/abstract=3561438

Council for Trade‐Related Aspects of Intellectual Property Rights (2020). Waiver from Certain Provisions of the TRIPS Agreement for the Prevention, Containment and Treatment of COVID-19: Communication from India and South Africa, World Trade Organization, IP/C/W. Online: https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=q:/IP/C/W669.pdf&Open=True

Cseres, K. J. (2005). Competition Law and Consumer Protection. Kluwer Law International.

Cserne, P. (2012). Freedom of Contract and Paternalism: Prospects and Limits of an Economic Approach. Springer.

DW (2021). Germany Rejects US Push to Waive COVID Vaccine Patents. Online: https://www.dw.com/en/germany-rejects-us-push-to-waive-covid-vaccine-patents/a-57453453

Eakin, B. (2021). Brazil Senate Passes COVID Vaccines License-Waiver Bill. Online: https://www.law360.com/articles/1412275/brazil-s-senate-passes-covid-vaccines-license-waiver-bill?copied=1

European Commission (2020a). Communication from the Commission Temporary Framework for assessing antitrust issues related to business cooperation in response to situations of urgency stemming from the current COVID-19 outbreak, Brussels, 8.4.2020 C(2020) 3200, final.

European Commission (2020b). The EU Commission Approves the German ʻUmbrella’ Scheme to Support Research, Development and Testing as well as Production of COVID-19 Relevant Products. Art. N° 94568. Online: https://www.concurrences.com/en/bulletin/news-issues/april-2020/the-eu-commission-approves-german-umbrella-scheme-to-support-research

European Commission (2021a). Comfort Letter. Cooperation at a Matchmaking Event: Towards COVID19 vaccines upscale production, 25/03/2021.

European Commission (2021b). EU Vaccines Strategy. Online: https://ec.europa.eu/info/live-work-travel-eu/coronavirus-response/public-health/eu-vaccines-strategy_en

European Commission (2021c). State aid Rules and Coronavirus. Online: https://ec.europa.eu/competition/state_aid/what_is_new/covid_19.html

European Commission DGC (2020). Comfort Letter: Coordination in the Pharmaceutical Industry to Increase Production and to Improve Supply of Urgently Needed Critical Hospital Medicines to Treat COVID-19 Patients. Brussels, 08/04/2020 COMP/OG – D (2020/044003).

Financial Times (2021, August 1). Pfizer and Moderna raise EU Covid vaccine prices. Online: https://www.ft.com/content/d415a01e-d065-44a9-bad4-f9235aa04c1a

Hellenic Competition Commission (2020). The Interim Results of HCC’s Investigations on Health and Hospital Equipment During Covid-19 Pandemic. Online: https://www.epant.gr/en/enimerosi/press-releases/item/1083-press-release-the-interim

Huizen, J. A. (2021, April 9). Herd immunity may take 4.6 years due to vaccine nationalism. MedicalNewsToday. Online: https://www.medicalnewstoday.com/articles/herd-immunity-may-take-4-6-years-due-to-vaccine-nationalism#Continuing-the-inequity

Icelandic Competition Authority (2020, March 22). The Icelandic Competition Authority opens an information center as a response to the antitrust challenges posed by the current COVID-19 outbreak. e-Competitions March 2020, Art. N° 93892. Online: https://www.concurrences.com/en/bulletin/news-issues/march-2020/the-icelandic-competition-authority-opens-an-information-center-as-a-response

International Federation of Pharmaceutical Manufacturers & Associations (2021). Statement on WTO TRIPS Intellectual Property Waiver. Online: https://www.ifpma.org/resource-centre/ifpma-statement-on-wto-trips-intellectual-property-waiver/

Jecker, N. S. & Atuire, C. A. (2021). What’s Yours is Ours: Waiving Intellectual Property Protections for COVID-19 Vaccines. Journal of Medical Ethics, 595–598.

Jenny, F. (2020). Covid-19 and the future of competition law enforcement. Competition Law International 16(1).

Kang, H., McMahon, A., Dutfield, D., McDonagh, L. & Thambisetty, S. (2021). Academic Open Letter in Support of the TRIPS Intellectual Property Waiver Proposal. LSE Law – Policy Briefing Paper, No. 46. Online: https://doi.org/10.2139/ssrn.3885568

Lo Bianco, F. (2020). Comparative Patent Compulsory Licensing under COVID-19. SSRN 3580407, 1–4.

Love, J. (2021). Would Exempting COVID-19 Vaccines from Intellectual Property Rights Improve Global Access and Equity? Online: https://www.cgdev.org/debate/would-exempting-covid-19-vaccines-intellectual-property-rights-improve-global-access

Mathieu, E., Ritchie, H., Ortiz-Ospina, E., Roser, M., Hasell, J., Appel, C., Giattino, Ch. & Rodés-Guirao, L. (2021). A Global Database of COVID-19 Vaccinations. Nature Human Behaviour 5, 947–953. Online: https://doi.org/10.1038/s41562-021-01122-8

McCauley, S. M. & Christiansen, M. H. (2019). Language Learning as Language Use: A Cross-Linguistic Model of Child Language Development. Psychological Review, 126(1), 1–51. Online: https://doi.org/10.1037/rev0000126

McMahon, A. (2021). Global Equitable Access to Vaccines, Medicines and Diagnostics for COVID-19: The Role of Patents as Private Governance. Journal of Medical Ethics, 47(3), 142–148. Online: https://doi.org/10.1136/medethics-2020-106795

Office of the United States Trade Representative (2021). Statement from Ambassador Katherine Tai on the Covid-19 Trips Waiver. Online: https://ustr.gov/about-us/policy-offices/press-office/press-releases/2021/may/statement-ambassador-katherine-tai-covid-19-trips-waiver

Pitruzzella, G. & Arnaudo, L. (2017). On Vaccines, Pharmaceutical Markets, and a Role for Competition Law in Protecting (also) Human Rights. European Competition Law Review, 7(38), 347–352. Online: https://doi.org/10.2139/ssrn.3033879

Rakić, I. (2020). Competition Law in the Age of Covid-19. Anali Pravnog fakulteta u Beogradu, 20.

Roope, L. S. et al. (2020). How should a Safe and Effective COVID-19 Vaccine be Allocated? Health Economists Need to be Ready to Take the Baton. PharmacoEconomics-open, 4(4), 557–561. Online: https://doi.org/10.1007/s41669-020-00228-5

Sangameshwaran, R. (2021). Understanding Germany’s Trenchant Opposition to the TRIPS Waiver. Online: https://genevahealthfiles.substack.com/p/understanding-germanys-trenchant

Son, K. B. (2019). Importance of the Intellectual Property System in Attempting Compulsory Licensing of Pharmaceuticals: A Cross-Sectional Analysis. Globalization and Health, 15(1), 1–8. Online: https://doi.org/10.1186/s12992-019-0485-7

Ssenyonjo, M. (2011). Reflections on State Obligations with Respect to Economic, Social and Cultural Rights in International Human Rights Law. The International Journal of Human Rights, 15(6), 969–1012. Online: https://doi.org/10.1080/13642981003719158

Statista (2021a). Global Vaccine Market Revenues from 2014 to 2020 in Billion US Dollars. Online: https://www.statista.com/statistics/265102/revenues-in-the-global-vaccine-market

Statista (2021b). Operating Loss of BioNTech SE from 2017 to 2020. Online: https://www.statista.com/statistics/1186022/operating-loss-biontech-se/

The United Nations (2015). Transforming Our World: The 2030 Agenda for Sustainable Development.

Tobin, J. (2012). The Right to Health in International Law. Oxford University Press.

Vercler, C. (2020). Navigating the Ethical Scylla and Charybdis of the COVID Vaccine. Journal of Pediatric Rehabilitation Medicine, 13(3), 229–231. Online: https://doi.org/10.3233/prm-200025

Williams, O. D. (2020). COVID-19 and Private Health: Market and Governance Failure. Development 63(2), 181–190. Online: https://doi.org/10.1057/s41301-020-00273-x

Williston, S. (1920). Freedom of Contract. Cornell Law Quarterly, 6(4), 365–380.

World Health Organization (2002). Implications of the Doha Declaration on the TRIPS Agreement and Public Health. Online: https://apps.who.int/iris/handle/10665/67345

World Health Organization (2021a). Coronavirus Disease Vaccines. Online: https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-vaccines

World Health Organization (2021b). Director-General’s Opening Remarks at 148th Session of the Executive Board. Online: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-148th-session-of-the-executive-board

Yu, Z., Razzaq, A., Rehman, A., Shah, A., Jameel, K. & Mor, R. S. (2021). Disruption in Global Supply Chain and Socio-Economic Shocks: A Lesson from COVID-19 for Sustainable Production and Consumption. Operations Management Research. pp. 1–16. Online: https://doi.org/10.1007/s12063-021-00179-y


Download data is not yet available.